0.8742

5.35% 0.0444

After Hours: .87 -0.0042 -0.48%

Werewolf Therapeutics Inc (HOWL)

Overview News Price History Option Chain Financials Discussions Forecast

Werewolf Therapeutics Inc stock is traded at $0.8742, with a volume of 191.79K. It is up +5.35% in the last 24 hours and down -22.64% over the past month. Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Previous Close:

$0.8298

Open:

$0.8557

24h Volume:

191.79K

Relative Volume:

0.77

Market Cap:

$38.45M

Revenue:

$19.94M

Net Income/Loss:

$-37.37M

P/E Ratio:

-0.8406

EPS:

-1.04

Net Cash Flow:

$-33.38M

1W Performance:

+1.91%

1M Performance:

-22.64%

6M Performance:

-75.92%

1Y Performance:

-85.65%

1-Day Range:

$0.8221

$0.915

1-Week Range:

$0.7868

$0.9425

52-Week Range:

$0.595

$6.89

Werewolf Therapeutics Inc Stock (HOWL) Company Profile

Name

Werewolf Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (665)

Phone

617-952-0555

Address

200 TALCOTT AVENUE, WATERTOWN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

HOWL's Discussions on Twitter

Compare HOWL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HOWL Werewolf Therapeutics Inc	0.8742	38.45M	19.94M	-37.37M	-33.38M	-1.04
VRTX Vertex Pharmaceuticals Inc	490.47	128.67B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	585.49	60.99B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	599.87	36.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	236.75	29.89B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	252.77	25.74B	3.81B	-644.79M	-669.77M	-6.24

Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-03-24	Initiated	JMP Securities	Mkt Outperform
Aug-24-23	Initiated	Wedbush	Outperform
Jun-06-23	Resumed	Jefferies	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-25-21	Initiated	Evercore ISI	Outperform
May-25-21	Initiated	H.C. Wainwright	Buy
May-25-21	Initiated	Jefferies	Buy
May-25-21	Initiated	SVB Leerink	Outperform

View All

Werewolf Therapeutics Inc Stock (HOWL) Latest News

Apr 21, 2025

Werewolf Therapeutics stock maintains $4 target, Market Outperform By Investing.com - Investing.com India

Apr 21, 2025

Werewolf Therapeutics stock maintains $4 target, Market Outperform - Investing.com

Apr 21, 2025

Apr 17, 2025

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - GlobeNewswire

Apr 17, 2025

Cancer Drug Developer Werewolf Therapeutics Strengthens Leadership Team Amid Promising Clinical Results - Stock Titan

Apr 17, 2025

Apr 03, 2025

Werewolf Therapeutics stock hits 52-week low at $0.85 - Investing.com Australia

Apr 03, 2025

Werewolf Therapeutics stock hits 52-week low at $0.85 By Investing.com - Investing.com South Africa

Apr 03, 2025

Mar 31, 2025

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Mar 31, 2025

Werewolf Therapeutics Reveals Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan

Mar 31, 2025

Bank of New York Mellon Corp Grows Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Mar 31, 2025

Mar 26, 2025

Werewolf Therapeutics stock hits 52-week low at $1.02 By Investing.com - Investing.com Australia

Mar 26, 2025

HC Wainwright Reaffirms Buy Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World

Mar 14, 2025

Wedbush Reaffirms Outperform Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World

Mar 14, 2025

Mar 12, 2025

Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Mar 12, 2025

Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China - TipRanks

Mar 12, 2025

Mar 11, 2025

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 11, 2025